 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Third Wave Technologies, Inc.
 |
Third Wave Technologies, Inc. |
 |
 |
 |
NEWS FROM THE STANDARD |
 |
IPO Weekly: Investors Cozy Up to KPMG Consulting
Feb 09 2001 04:18 PM PST
PROFILE |
 |
Third Wave Technologies develops assays that detect genetic variations in DNA, RNA, and viruses. Its Invader line of products includes tests for genetic mutations associated with immune response, drug metabolism, and predisposition to blood clots. Doctors use the company's tests in patient diagnosis and treatment and therapeutic monitoring; drug companies use them to discover and develop pharmaceuticals. Third Wave has collaborative agreements through which it develops assays for such firms as Novartis, Applied Biosystems, and a unit of GlaxoSmithKline. It has also licensed its technology to Stanford University. Investors in the company include The Wellcome Trust.
COMPETITION |
 |
Nanogen, Inc. (NGEN)
Orchid BioSciences, Inc. (ORCH)
Sequenom, Inc. (SQNM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 11.40
1-Yr. Sales Growth: 343.6%
Employees: 247
Revenue per employee: $46,153.85
KEY PEOPLE |
 |
Lance Fors
CEO
CONTACT INFO |
 |
502 S. Rosa Rd.
Madison, WI 53719
US
Phone: 608-273-8933
Fax: 608-273-8618
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |